ArticleJournal of the American Geriatrics Society2022
"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.
Article in Journal of the American Geriatrics Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Eligibility for donanemab trial in a population-based study of cognitive aging.The journal of prevention of Alzheimer's disease · 2025Trial
- Eligibility for lecanemab treatment in a French memory clinic setting.Journal of neurology · 2026Observational
- Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Article
- Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer's disease to individuals with mild cognitive impairment or early Alzheimer's disease in the general population.European journal of epidemiology · 2025Article
- Validation and convergent validity of the Boston cognitive assessment (BOCA) in an Italian population: a comparative study with the Montreal cognitive assessment (MoCA) in Alzheimer's disease spectrum.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real-word study on aducanumab and lecanemab.European journal of neurology · 2025Article
- Challenges for emergency departments: Anti-amyloid therapy and amyloid-related imaging abnormalities in persons with dementia.Journal of the American Geriatrics Society · 2024Article
- Article
- Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort.Journal of neurology · 2024Article
- Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators.The journal of prevention of Alzheimer's disease · 2024Article
- Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.Neurology · 2023Article
- Home-based transcranial alternating current stimulation (tACS) in Alzheimer's disease: rationale and study design.Alzheimer's research & therapy · 2023Article
- Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer's disease.Translational neurodegeneration · 2023Article
- Understanding Barriers Along the Patient Journey in Alzheimer's Disease Using Social Media Data.Neurology and therapy · 2023Article
- Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline.Journal of neurology · 2023Article
- The new therapy for Alzheimer's disease: from a hope for a few to a false hope?Aging clinical and experimental research · 2022Article
- Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.International journal of geriatric psychiatry · 2022Article
- Modifiable risk factors for dementia, and awareness of brain health behaviors: Results from the Five Lives Brain Health Ireland Survey (FLBHIS).Frontiers in psychology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.